HOME >> BIOLOGY >> NEWS
Cell Pathways scientists describe mechanism by which SAANDS compounds trigger programmed death in cancerous and precancerous cells

ction of cGMP-dependent protein kinase G (PKG). This rise in PKG activity causes beta-catenin to be degraded in neoplastic cells, thus triggering cell death by apoptosis through well-studied mechanisms. In addition, SAANDs that are better inhibitors of PDE5 and PDE2 than exisulind also show parallel increases in ability to induce apoptosis and inhibit growth of the cancer cells.

"Exisulind and other SAANDs appear to act at an early point in the biochemical pathway that controls apoptosis and survival of cancer cells," said W. Joseph Thompson, Ph.D., vice president of research at Cell Pathways and lead author of the publication. "Our initial data indicates that increased PDE5 expression, and in some cases PDE2, occurs in precancerous and cancerous lesions. This over-expression appears to keep cGMP low in cells that have abnormal proliferation or apoptosis rates. The data indicate that by inhibiting cGMP PDE activity in cancer cells, a sustained rise in cGMP occurs, triggering cell death through protein kinase G. In normal cells, the cGMP pathway does not appear to be important in the regulation of apoptosis. Exisulind and other SAANDs restore the ability of abnormal cells to die by inhibiting that cGMP PDE activity."

New Insights in the Biology of Cancer

Cyclic nucleotide PDEs consist of 11 gene families, each having one or more different members or "isoforms." Each family of PDEs is characterized by their ability to bind and degrade cyclic AMP (cAMP) and/or cGMP, but differs in their immunological, physical and kinetic properties. Only a limited number of PDE isoforms are expressed and used by any single type of cell or tissue to regulate cGMP or cAMP levels. Pharmaceutical developers have been studying these enzymes as potential drug targets to modulated cyclic nucleotide levels in diseases where their levels are important, such as asthma and heart disease. Until now, PDE inhibitors have not been developed as anti-cancer agents. Mo
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
4-Jul-2000


Page: 1 2 3

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Pathways of emotion from cortex to peripheral organs
3. Cell Pathways CP461 demonstrates multiple anti-cancer activities
4. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
5. Pitt Researchers Find Way To Block Cellular Growth Pathways And Inhibit Tumor Growth
6. Discovery Of Genetic Pathways May Provide New Ways To Combat Candida Infections
7. DNA lends scientists a hand, revealing new chemical reactions
8. Conference at UH opens doors for new scientists, engineers
9. Wisconsin scientists develop quick botox test
10. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
11. Alaska scientists find Arctic tundra yields surprising carbon loss

Post Your Comments:
(Date:5/21/2013)... -- Over the past few decades, scientists have developed ... balloons and metallic stents. While generally effective, each of ... effects. , A new study from MIT analyzes the ... benefits of angioplasty balloons and drug-releasing stents, but may ... is inflated in the artery for only a brief ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
(Date:5/21/2013)... 2013  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... infectious diseases, announced today that Jeffrey Riley ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hyatt Hotel. Mr. Riley is scheduled to present at 10:00 ... Biologics, presentation can be accessed by logging onto the web ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
(Date:5/21/2013)... The Formulate Fusion Fabric Display Kit ... marketing teams looking for a fully-functional package for their trade ... you’ll need to put together a stunning and eye-catching trade ... number of displays and accessories that can be quickly assembled ... feet in size. These components vary from kit to kit, ...
(Date:5/20/2013)... , May 20, 2013  MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants processed ... secured a revolving line of credit with Bank of ... secured by the Company,s accounts receivable and inventory, allows ... 1, 2014.  The facility will be used for general ...
Breaking Biology Technology:Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2
Cached News: